- Home
- ALEC
ALEC
Alector Inc.
as 07-26-2024 4:00pm EST
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Upcoming Earnings Alert:
Get ready for potential market movements as Alector Inc. ALEC prepares to release earnings report on 01 Aug 2024.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 425.1M | IPO Year: | 2019 |
| Target Price: | $14.17 | AVG Volume (30 days): | 664.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.66 - $9.07 | Next Earning Date: | 08-01-2024 |
| Revenue: | $96,406,000 | Revenue Growth: | -23.30% |
| Revenue Growth (this year): | -32.33% | Revenue Growth (next year): | 72.74% |
Stock Insider Trading Activity of Alector Inc. (ALEC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Jun 3 '24 | Sell | $4.80 | 13,206 | $63,372.95 | 305,641 | SEC Form 4 |
| Romano Gary | ALEC | Chief Medical Officer | Jun 3 '24 | Sell | $4.80 | 8,040 | $38,581.55 | 188,273 | SEC Form 4 |
| Rosenthal Arnon | ALEC | Chief Executive Officer | Jun 3 '24 | Sell | $4.80 | 25,135 | $120,617.84 | 1,975,245 | SEC Form 4 |
| GRASSO MARC | ALEC | Chief Financial Officer | Jun 3 '24 | Sell | $4.80 | 6,920 | $33,207.70 | 138,037 | SEC Form 4 |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Mar 4 '24 | Sell | $6.92 | 10,169 | $70,386.77 | 318,847 | SEC Form 4 |
| GRASSO MARC | ALEC | Chief Financial Officer | Mar 4 '24 | Sell | $6.92 | 5,716 | $39,561.58 | 144,957 | SEC Form 4 |
| Romano Gary | ALEC | Chief Medical Officer | Mar 4 '24 | Sell | $6.92 | 6,001 | $41,553.92 | 196,313 | SEC Form 4 |
| Rosenthal Arnon | ALEC | Chief Executive Officer | Mar 4 '24 | Sell | $6.92 | 18,837 | $130,385.95 | 2,000,380 | SEC Form 4 |
| Rosenthal Arnon | ALEC | Chief Executive Officer | Dec 4 '23 | Sell | $5.56 | 23,831 | $132,500.36 | 2,019,217 | SEC Form 4 |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Dec 4 '23 | Sell | $5.56 | 12,519 | $69,605.64 | 329,016 | SEC Form 4 |
| GRASSO MARC | ALEC | Chief Financial Officer | Dec 4 '23 | Sell | $5.56 | 4,574 | $25,431.44 | 150,673 | SEC Form 4 |
| Romano Gary | ALEC | Chief Medical Officer | Dec 4 '23 | Sell | $5.56 | 5,035 | $27,994.60 | 202,314 | SEC Form 4 |
Latest Alector Inc. News
ALEC Breaking Stock News: Dive into ALEC Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
Insider Monkey
a month ago
Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating?
Zacks
a month ago
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
GlobeNewswire
a month ago
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
2 months ago
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
Compare ALEC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALEC Alector Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.